Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: yes

Brief summary:
To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics (PK) of single rising doses of BI 416970. A further objective is to assess the influence of CYP2C9 phenotype on the PK of BI 416970.

Detailed description:

Arms:
arm 1: single rising dose given as tablet

Interventions: intervention 1: Placebo to BI 416970 intervention 2: BI 416970
Intervention descriptions: intervention 1: single rising doses intervention 2: single rising doses

Protocol document: